Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to new studies, some cancer patients can safely forego radiation therapy.

2.

Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Can Exercise Extend Survival After Breast Cancer?

5.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot